Dermal recall effect in breast radiotherapy patients after vaccine administration
Virginia Garcia Reglero,
Spain
PO-1176
Abstract
Dermal recall effect in breast radiotherapy patients after vaccine administration
Authors: Virginia García Reglero1, Sara Vazquez Gonzalez2, Elena García Alonso3, Jose Enrique Baquedano Baquedano3, Rogelio Robaina3, Marta Bonet Beltran3, David González gómez3, Lucia Tueros Farfan4, Najoua El Jarroudi5, Moises Mira Flores3
1H.U Arnau de Vilanova, Radiation Oncology , Lleida, Spain; 2H.U Arnau de Vilanova , Radiation Oncology, Lleida, Spain; 3H.U Arnau de Vilanova, Radiation Oncology, Lleida, Spain; 4H.U Arnau de Vilanova, radiation Oncology, Lleida, Spain; 5H.U Arnau de Vilanova, radiation Oncology, lleida, Spain
Show Affiliations
Hide Affiliations
Purpose or Objective
The dermal
recall phenomenon is an increase in the sensitivity of stem cells in the area
of the treatment field and may lead to increased acute toxicity.
Afterwards,
the recall effect has been described in those patients who have been vaccinated
against COVID during radiotherapy treatment.
Our objective has been to observe if we are
facing a dermal recall phenomenon after the administration of the vaccine in
patients who are on the course of radiotherapy.
Material and Methods
Coinciding
with the vaccination campaign against SARS-CoV-2 in oncological patients, which
began in our environment in March 2021, we have collected data on radiodermatitis that have been presented by 42 patients after the end of
radiation therapy treatment for breast cancer
Results
The
percentage of patients vaccinated were as follows: 57% (24/ 42 patients)
Of which
6/24 patients received the vaccine dose during radiation therapy
Of the 42
patients treated with radiation therapy, 3 had a degree 3 dermal toxicity.
These 3 patients were given the vaccine during radiotherapy treatment, which
accounts for 50% of the patients vaccinated during radiotherapy.
Note that
of the 845 patients treated with hypofractionation radiotherapy since 2016 only
0.23% have presented grade 3 acute radiodermatitis, versus 7% of the patients
who have been vaccinated during radiotherapy
Conclusion
We estimate
that most likely, the vaccine carries a greater risk of skin toxicity mediated
by the dermal recall phenomenon but that does not mean that the administration
of the vaccine should be contraindicated, but more closely warn patients who
receive the vaccine during radiation therapy.